Ludwig-Maximilians University of Munich (LMU) is one of the oldest and most prestigious universities in Germany. The University possesses an excellent infrastructure for innovative basic research and the translation of its insights into applied technologies. LMU’s exceptional performance in the Excellence Initiative, a nationwide competition designed to boost cutting-edge research at German universities, is a testament to the University’s dedication to quality research and teaching. In the Institute of Pharmacology, Toxicology, and Pharmacy, research focuses on different phases of CNS drug development from target identification to assessment of efficacy and tolerability of drug candidates. One main area of interest is the elucidation of processes that contribute to the development, progression and therapy resistance of epilepsies in humans and animals. To accomplish this, we investigate epilepsy in various genetic and induced rodent models. In our studies we apply methods that include video- and EEG- monitoring, behavioural tests, in vivo imaging and immunohistochemistry. In the past collaborative efforts with pharmaceutical companies have successfully contributed to the marketing of novel antiepileptic drugs. Our research record is evidenced through our participation in projects financed by the EU Seventh Framework program, and additionally our involvement in coordinated projects supported by the German Research Foundation (DFG).